Precision medicine is a groundbreaking approach to healthcare that individualizes medical treatments for patients. Unlike the traditional “one-size-fits-all” approach, precision medicine allows for more accurate, effective, and targeted treatments, improving patient outcomes and minimizing side effects.
By leveraging technology, such as genetic sequencing, biomarker identification, and bioinformatics, precision medicine enables doctors to identify the most appropriate therapies for each patient.
Some of the key benefits of Precision Medicine are the creation of personalized treatment plans, disease predisposition detection and prevention, targeted therapy development and reduced risks of adverse reactions.
Precision Medicine is applicable in various fields, such as cancer, neurology, cardiology, rare diseases and other.
GeneKor specializes in molecular genetics and immunohistopathology.
GeneKor is a multinational company founded in 2007. It operates a network of molecular biology and histopathology labs in Europe, offering the necessary tools to the physicians for early detection, diagnosis, prognosis and personalized treatment for patients in oncology, cardiology, neurology and pharmacogenetics, using cutting-edge technology, expert-driven research and a patient-centric approach.
In our accredited laboratories we provide a variety of certified molecular genetics and immunohistopathology services, using state-of-the-art technology. The tests performed at GeneKor empower physicians to perform precision medicine in their everyday clinical practice.
Our focus is on oncology, rare diseases and pharmacogenomics. Our aim is to achieve the most thorough, valid and cost-effective diagnostic procedure to improve patient care.
Patients Worldwide
Countries
Doctors
Clinics
Publications
Nikolaos Tsoulos1, Konstantinos Agiannitopoulos1, Kevisa Potska1, Anastasia Katseli1, Christina Ntogka1, Georgia Pepe1, Dimitra Bouzarelou1, Athanasios Papathanasiou1, Dimitrios Grigoriadis1, Georgios N. Tsaousis1, Helen Gogas2, Theodore Troupis3, Konstantinos Papazisis4, Ioannis Natsiopoulos5, Vassileios […]
CHRISTOS MARKOPOULOS1, NIKOLAOS TSOULOS2, KONSTANTINOS AGIANNITOPOULOS2 and EVANGELIA KARAGIANNI3
Eirini Papadopoulou, PhD1 ; George Rigas, MD2; Elena Fountzilas, MD, PhD3 ; Anastasios Boutis, MD, PhD4; Stylianos Giassas, MD5; Nikolaos Mitsimponas, MD, MSc6; Danai Daliani, MD7 ; Dimitrios C Ziogas, […]
PR status cannot predict Oncotype DX Recurrence Score®: a study in a Greek cohort of N0M0/ER+/PR-/HER2- breast cancer patients tested with Oncotype DX
The prognostic and predictive value of Oncotype DX® in ER+/HER2-/pT2N0, cM0 Breast Cancer Patients
The importance of pre- and post-genetic counselling for genetic testing in hereditary cancer
Low level constitutional mosaicism in breast cancer patients
MAPPING OF GENE VARIANTS IN 7,587 SUBJECTS REFERRED FOR HEREDITARY CANCER
Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer
Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers.
Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes
Copy Number Variations (CNVs) and Hereditary Breast Cancer
Multigene panel testing results for hereditary breast cancer - ESMO 2019
Tumor Mutational Burden TMB - poster at ECCB 2018
Analysis of hereditary cancer syndromes by use of a panel of genes: More answers than questions
BRCA Early Access program - poster at ECP
CTRC-AACR San Antonio Breast Cancer Symposium 2014
St. Gallen 2013 OncotypeDX
St. Gallen 2013 BRCA
EANO 2012
ASCO 2012 EGFR
ASCO 2012 ALK
St. Gallen 2011
ESMO 2011 ALK
ESMO 2011 EGFR